Posted from: Friday, July 07, 2017 - 02:28 PM - Present

Cotempla XR-ODT Approved for Treatment of ADHD

June 19, 2017 – The U.S. FDA has approved once-daily Cotempla XR-ODT™ (methylphenidate) extended-release orally disintegrating tablets, manufactured by Neos Therapeutics. Cotempla XR-ODT is indicated to treat attention deficit hyperactive disorder (ADHD) in children and teens between 6 and 17 years of age. Launch is planned for the autumn of 2017 in blister-packages containing 8.6mg, 17.3mg or 25.9mg tablets. Because it is a C-II controlled substance, Cotempla XR-ODT has a medication guide for patients and a boxed warning about its possible abuse, misuse and/or dependence.

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by U.S. mail or by fax.

Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

 

 

Last Updated Saturday, September 23, 2017 - 06:45 AM.